Background The electronic health record (EHR) is the major repository of clinical data in the NHS. It is a huge potential resource but remains severely under-utilised to the point that almost none of the UK's audit and research output is based on routinely collected clinical data. The reasons are complex but ultimately reflect the fact that these data are rarely entered into the EHR in a form that allows for their organised storage and digital download.

Methods We have developed a SNOMED-based electronic powerform comprising a user-friendly interface for real-time entry of clinical data into the hospital EHR during cardiac outpatient consultation. Our aim was to capture outpatient clinical data in a form that allows for automatic development of summary patient reports and for batch download of deidentified data for audit and research.

Results During the first 4 months after installation of the powerform, consultant utilisation averaged 60% for the 327 new patients seen during that period. Presenting symptoms, examination findings, investigations, diagnosis, initial treatment and disposal (>120 fields) were entered in real time during consultation and a structured summary report was developed. This was made available for electronic transfer directly into the patients EMIS file in the primary care record, permitting same-day delivery of the report and obviating the need for a dictated clinic letter. Batched download of the digital data was successful, with sample analytic findings as follows:

Patient ethnicity South Asian 44%, white 34%, black 15% Presenting symptom Chest pain 41%, dyspnoea 11%, palpitations 10%, dizzy attacks/syncope 8%, hypertension 7% Diagnosis Non-cardiac chest pain 24%, angina 11%, coronary

disease 7% Disposal discharged to GP 74%, follow-up appointment 11%, cath lab waiting list 6%, referral to specialist clinic 9%.

Ongoing are surveys of satisfaction with the power forms (cardiologists) and with the summary reports (GPs).

Conclusion This is the first report of powerform development for entry of routinely collected cardiac outpatient data into the hospital EHR. The data are stored in a form that permits: (1) automatic generation of a summary report for same-day delivery into the primary care record and (2) batch download of de-identified digital data for audit. Integration of the system with programmes of generic patient consent will open up the EHR to real-world clinical research.

101 EFFECT OF OXYGEN THERAPY IN EARLY NEOTNATAL
LIFE ON CAPILLARY MICROCIRCULATION AND BLOOD
PRESSURE IN LOW BIRTH WEIGHT INFANTS

¹Rajendra Raghuraman, ²Donovan Duffy, ²Isaac Manyondaa, ¹Tarek Antonios*. ¹St George's, University of London; ²St George's University Hospitals NHS Foundation Trust

10.1136/heartjnl-2017-311726.100

Background Low birth weight (LBW) is a risk factor for adult essential hypertension, diabetes mellitus, obesity and cardiovascular disease mortality in later life. Individuals with history of LBW have many abnormalities in their blood vessels including a reduction in microvascular density or rarefaction. Capillary rarefaction (CR) is a hallmark of essential hypertension and evidence suggests that CR is a primary structural abnormality that precedes the onset of the rise in blood pressure (BP) as it is found in normotensive individuals at high risk of developing hypertension. We recently found that LBW infants have higher and not lower capillary density at birth. We hypothesised that LBW infants will undergo significant CR in early life triggered or exaggerated by oxygen therapy.

Methods We studied 26 LBW infants and 14 normal birth weight infants (NBW) as controls. Of the LBW infants, only 10 received oxygen therapy. We used a handheld video capillaroscopy system (HVCS) to measure functional or basal (BCD) and structural or maximal capillary density (MCD) on

					Investigation	ns Ordered	
			Barts He	alth NHS			
			NHS	Trust	ECG		
					Blood Tests		
Ca	rdiac Out	tnatient Reno	t New Refer	rral	Imaging	Itasina	
Cardiac Outpatient Report New Referra				ıaı	Ambulatory monitoring Stress Testing		
C	- Ad Ti		****		Suess resung		
Consultant: L	or Adam Tim	mis / Date Seen: 31	AUG-2016		Treatment		
					Drug	Dose & Freque	incy
GP Name: Patient First Name:				Amlodipine 10mg Once Per Day		er Day	
GP Address: Patient Last Name:					Ramipril	10mg Once Pe	
MRN Number: NHS Number:					Atorvastatin	80mg Once Pe	
	Sex:					10mg Once Pe	
		DOB:	(64 Years)		Metformin	500mg Three	Per Day
		Address:	(01 10010)				1330,730,11
					Further Man	annent:Dies	harge to GP, Refer Specialist Clinic
12010					Further Mana	igement.Disc	narge to GF, Refer Specialist Clinic
Primary Com	plaint: Hyper	rtension			Waiting List:		
1-11	202 1000				Specialist Clini	c:	Hypertension
Secondary C	omplaint(s):				Comments to C	P:	100 mile 10 Mars - 10 Mars
					Additional Com	ments:	Poorly controlled BP on ramipril 10 and amlodipine 10
					1		daily
Risk Factors					1		Please add spironolactone 25mg daily (eGFR 73 on 16/3/16)
Risk Factor							Meanwhile I have referred to hypertension clinic
			ever smoked, Hypertension, Diabetes		1		weathwille i have reletted to hypertension clinic
Hypertension Family history							
Prior Procedi	uroo				1		
Date	Procedure				1		
Date	Procedure				1		
Diagnosis					1		18
Date	Diagnosis		Confirmation	Ranking	1		
31-AUG-2016			Confirmed	Primary	1		
			Johnson		1		
Other Problem	ms				1		
Date	Problems & Dia	gnoses - Lifelong	Confirmation	Status	1		
31-AUG-2007 Nephrectomy		Confirmed	Active	1			
31-AUG-2004 Diabetes mellitus type II		Confirmed	Active				
31-AUG-2004 Dyslipidaemia		Confirmed	Active				
31-AUG-2004	Hypertension		Confirmed	Active	1		
District -				2 5 95	Printed by: Tim	mis. Adam	Page2 of 2
	nis, Adam ug/2016 11:06			Page1 of 2 (Continued)	Printed on: 31/	Aug/2016 11:06	(End of Report)

Abstract 100 Figure 1

Heart 2017;**103**(Suppl 5):A1–A162

day 1, 5, and 10, and after 40 weeks adjusted for the gestational age in preterm LBW infants. Blood pressure was measured at each visit using Welch Allyn VSMTM 300 monitor. Results At birth, the NBW infants had significantly lower BCD (difference -9.3 cap/area, 95% CI: -1.5 to -17.1, p=0.021) and MCD (difference -12.6 cap/area, 95% CI: -1.5 to -21.7, p=0.025) compared to the LBW infants. LBW oxygen group had a significantly lower SBP (mean difference -9.5 mmHg, 95% CI: -1 to -19, p=0.047), DBP (difference -13 mmHg, 95% CI: -4 to -22, p=0.009). At 40 weeks old, the LBW oxygen group showed a significant reduction in BCD (difference -19.3 cap/area, 95% CI: -9 to -30, p=0.003) and MCD (difference -22 cap/area, 95% CI: -8 to -36 p=0.007). Similarly the LBW non-oxygen group had a significant reduction in BCD (difference -29 cap/area, 95% CI -17 to -41 p<0.0001) and MCD (mean difference -29 cap/area, 95% CI, -16 to -41 p<0.001). Both LBW groups showed a significant rise in BP. The rise in SBP (mean difference 24 mmHg, 95% CI: 14-34, p<0.0001) and DBP (mean difference 14 mmHg, 95% CI: 7-22, p<0.001) was more pronounced in LBW oxygen group compared to the LBW control group (difference 14 mmHg, 95% CI: 0.5-27, p=0.043 and difference 9 mmHg, 0.3–19, p=0.056 respectively)

Conclusions We confirm that LBW infants have higher capillary density at birth but develop significant capillary rarefaction and increase in their blood pressure at 40 weeks compared to NBW infants. Oxygen therapy in the neonatal period in LBW infants was associated with higher blood pressure levels but we could not detect any effect on capillary rarefaction. Further studies are needed to investigate the humoral factors that trigger the changes of microcirculation in LBW infants during the neonatal period which may be of importance in preventing hypertension in later life.

102 EVOLUTION OF EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES SINCE 2000: A SYSTEMATIC APPRAISAL

¹Charles Badu-Boateng*, ²Arash Yavari, ³Rizwan Sarwar. ¹King's College London, GKT School of Medicine, London, UK; ²ohn Radcliffe Hospital, Cardiology Department, Oxford, UK; ³John Radcliffe Hospital, Cardiology Department, Oxford, UK

10.1136/heartjnl-2017-311726.101

Background Guidelines from the European Society of Cardiology (ESC) summarise the best available evidence in the management of cardiac disease. These guidelines are graded according to ESC-predefined scales of class of recommendation from I-III and levels of evidence from A-C. We evaluated the development of ESC guidelines since 2000.

Method We reviewed recommendations from all ESC guidelines from 2000–14, collating classes of recommendation and level of evidence for each. We assessed the number and percentages of each class of recommendation and determined temporal changes in proportion.

Results Out of 52 guidelines, we extracted 4547 recommendations, with 67% being in Class I or III, indicating unequivocal guidance. Regarding the level of evidence for these recommendations, we found that only 18% were class A, indicating high quality evidence, and 50% were class C, indicating consensus opinion or small studies. From 2000–2014, there were minor changes in the proportions of different classes of recommendation and levels of evidence.

Conclusions Medicine is rapidly changing and cardiologists face difficult challenges in the application of a growing

number of recommendations of difference evidence level to guide clinical practice. Our analysis highlights that 33% of all guideline statements are in the equivocal class (II), with 82% of guidelines not based upon the highest level of evidence. Over 14 years there have been minimal changes in proportions of class of recommendation and level of evidence. Our findings suggest the need to improve the level of evidence underpinning current guidance to increase the proportion of unequivocal guidance recommendations.

103

THE ABILITY OF CARDIOGONIOGMETRY COMPARED TO FLOW FRACTIONAL RESERVE AT IDENTIFYING PHYSIOLOGICALLY SIGNIFICANT CORONARY STENOSIS: THE CARDIOFLOW STUDY

¹·Oliver I Brown*, ²Andrew L Clark, ²Raj Chelliah, ²Benjamin Davison, ²Adam N Mather, ²Michael S Cunnington, ²Joseph John, ²Albert Alahmar, ²Richard Oliver, ²Konstantinos Aznaouridis, ²Angela Hoye. ¹Hull York Medical School; ²Hull and East Yorkshire Hospital NHS trust

10.1136/heartjnl-2017-311726.102

Introduction Cardiogoniometry (CGM) is method of 3-dimensional electrocardiographic assessment which has been previously shown to identify patients with angiographically defined, stable coronary artery disease (CAD). However, angiographic evidence of CAD, does not always correlate to physiologically significant CAD. The aim of our study was to assess the ability of CGM to detect physiologically significant coronary stenosis defined by fractional flow reserve (FFR).

Methods In a tertiary cardiology centre, patients with single vessel CAD were enrolled into a prospective double blinded observational study. A baseline CGM recording was performed at rest. A second CGM recording was then performed during the FFR procedure, at the time of maximal hyperaemia. A significant CGM result was defined as an automatically calculated ischaemia score < 0 and a significant FFR ratio defined as < 0.8. After enrolment, CGM and FFR results were compared and markers of diagnostic performance (sensitivity, specificity, positive predictive value and negative predictive value) were calculated at rest and during maximal hyperaemia. Statistical agreement between CGM and FFR was calculated by the Kappa statistic.

Results Forty patients were included (aged 61.1±11.0; 60.0% male), of which sixteen (40%) were found to have significant CAD when assessed by FFR. Markers of diagnostic performance of CGM are shown in the table.

Conclusion The diagnostic performance of CGM to detect physiologically significant stable CAD is poor at rest. Although, the diagnostic performance of CGM improves substantially during maximal hyperaemia, it does not reach sufficient levels of accuracy to be used routinely in clinical practice.

	CGM at rest (n=40)	CGM during maximal hyperaemia (n=40)
Sensitivity	31.3%	68.8%
Specificity	62.5%	54.2%
Positive predictive value	35.7%	50.0%
Negative predictive value	57.7%	72.2%
Kappa statistic for agreement	-0.06, p=0.64	0.21, p=0.15